Sort
64,565 grants matching “drug discovery”
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies
$829,650Donald W. Kufe · Dana-Farber Cancer Inst · U01 · FY2021 · CA
An integrated pipeline for accelerated plant natural product discovery
$829,520Christina D Smolke · Stanford University · U01 · FY2018 · GM
An integrated pipeline for accelerated plant natural product discovery
$829,520Christina D Smolke · Stanford University · U01 · FY2019 · GM
An integrated pipeline for accelerated plant natural product discovery
$829,520Christina D Smolke · Stanford University · U01 · FY2016 · GM
An integrated pipeline for accelerated plant natural product discovery
$829,520Christina D Smolke · Stanford University · U01 · FY2017 · GM
Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery
$829,484Bart Lee Staker · Seattle Children'S Hospital · R01 · FY2023 · AI
Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery
$829,484Bart Lee Staker · Seattle Children'S Hospital · R01 · FY2022 · AI
Targeting S-adenosylmethionine decarboxylase for HAT drug discovery
$829,317Margaret A. Phillips · Ut Southwestern Medical Center · R01 · FY2010 · AI
Development of a charge-sensitive optical detection system for high-throughput study of small molecules
$829,265Nguyen Ly · Biosensing Instrument, Inc. · R44 · FY2022 · GM
Translational Center on Serotonin and Stimulant Addiction
$829,243Kathryn A. Cunningham · University Of Texas Med Br Galveston · P20 · FY2012 · DA
Translational Center on Serotonin and Stimulant Addiction
$829,243Kathryn A. Cunningham · University Of Texas Med Br Galveston · P20 · FY2010 · DA
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
$829,212Jian Li · Monash University · R01 · FY2014 · AI
Predictive Smoking Cessation Preclinical Battery
$829,176Daniela Brunner · Psychogenics, Inc. · R44 · FY2012 · DA
Identification of Common Genetic Variants for Atrial Fibrillation and PR Interval
$829,164Patrick Thomas Ellinor · Massachusetts General Hospital · R01 · FY2013 · HL
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
$829,118David H Haussler · University Of California Santa Cruz · U24 · FY2010 · CA
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVAL
$829,096Patrick Thomas Ellinor · Massachusetts General Hospital · R01 · FY2018 · HL
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics
$828,594Michael Ohlmeyer · Atux Iskay Group Llc · R44 · FY2025 · AG
Nuclear Factor-kappaB in Ovarian Cancer
$828,564Christina Annunziata · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Developmental Funds
$828,396Ben H Park · Vanderbilt University Medical Center · P30 · FY2022 · CA
Developmental Funds
$828,396Ben H Park · Vanderbilt University Medical Center · P30 · FY2024 · CA
Developmental Funds
$828,396Jennifer A Pietenpol · Vanderbilt University Medical Center · P30 · FY2021 · CA
Developmental Funds
$828,396Ben H Park · Vanderbilt University Medical Center · P30 · FY2023 · CA
Developmental Funds
$828,350Jennifer A Pietenpol · Vanderbilt University Medical Center · P30 · FY2020 · CA
Development of GCPII inhibitors for the treatment of age-related cognitive disorders
$828,290Takashi Tsukamoto · Johns Hopkins University · R01 · FY2022 · AG
Identification of Common Genetic Variants for Atrial Fibrillation and PR Interval
$828,078Patrick Thomas Ellinor · Massachusetts General Hospital · R01 · FY2015 · HL